

**Supplementary Table 3.** Change of MASLD status in subgroups

	Pretreatment MASLD (+)				Pretreatment MASLD (-)				P-value
	MASLD persistence		MASLD regression		Non-MASLD persistence		MASLD emergence		
	(+)→(+)	(+)→(-)	(-)→(+)	(-)→(-)	(-)→(+)	(-)→(-)	(-)→(+)		
All patients	1,438 (72.4)	548 (27.6)	3,259 (84.6)	595 (15.4)	1,960 (34.0)	2,033 (34.8)	0.17		
HCV genotype 3	27 (96.4)	1 (3.6)	45 (90.0)	5 (10.0)	28 (35.9)	32 (41.0)	0.10		
Non-HCV genotype3	1,411 (72.1)	547 (27.9)	3,214 (84.5)	590 (15.5)	1,958 (34.0)	2,001 (34.7)	0.20		
Diabetes	466 (75.5)	151 (24.5)	759 (81.8)	169 (18.2)	617 (39.9)	635 (41.1)	0.31		
Non-diabetes	972 (71.0)	397 (29.0)	2,500 (85.4)	426 (14.6)	1,369 (31.9)	1,398 (32.5)	0.31		
BMI ≥23 kg/m <sup>2</sup>	1,179 (75.7)	378 (24.3)	1,660 (80.5)	401 (19.5)	1,557 (43.0)	1,179 (43.7)	0.41		
BMI <23 kg/m <sup>2</sup>	156 (51.2)	149 (48.9)	1,438 (90.4)	153 (9.6)	305 (16.1)	309 (16.3)	0.82		
Liver cirrhosis	351 (67.1)	172 (32.9)	1,248 (86.4)	196 (13.6)	523 (26.6)	547 (27.8)	0.21		
Non-liver cirrhosis	1,087 (74.3)	376 (25.7)	2,011 (83.4)	399 (16.6)	1,463 (37.8)	1,486 (38.4)	0.41		
FIB-4 ≥3.25	355 (63.9)	201 (36.1)	1,419 (88.0)	193 (12.0)	556 (25.6)	548 (25.3)	0.69		
FIB-4 <3.25	1,067 (75.6)	345 (24.4)	1,828 (82.1)	399 (17.9)	1,412 (38.8)	1,466 (40.3)	0.05		

MASLD, metabolic dysfunction-associated steatotic liver disease; BMI, body mass index; HCV, hepatitis C virus; FIB-4, fibrosis-4 index.